Tarsus Pharmaceuticals Inc. Common Stock (TARS)
Stock · NASDAQ · Health Care
$68.1as of 10/16/2026
Price chart
Active signals
TARS Signal Track Record
How signals performed across all stocks →What TARS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +0.3% | 53% | September 2, 2026 |
| Bollinger Band Breakout | 27 | -1.0% | 48% | September 2, 2026 |
| Bollinger Band BreakdownActive now | 19 | +4.1% | 63% | July 14, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +1.6% | 64% | August 13, 2026 |
| Any 20-session window (baseline) | +2.5% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospit…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 370
- Website
- www.tarsusrx.com/
Fundamentals
- 1-day range
- $70.55$74.94
- Market cap
- $2.81B
- P/E (trailing)
- —
- P/E (forward)
- -258.15
- EPS (trailing)
- $-1.08
- Dividend yield
- —
- Beta
- 0.32
- Avg. volume
- 834.8K
How Tarsus Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Tarsus Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Bobak R. Azamian · June 17, 2026 · Sale5.4K @ $61.81
- Bobak R. Azamian · June 17, 2026 · Sale4.6K @ $61.24
- Jeffrey S. Farrow · June 16, 2026 · Sale14.4K @ $60.95
- Jeffrey S. Farrow · June 15, 2026 · Option Exercise27.9K
- William J. Link, PhD · June 15, 2026 · Sale1.9K @ $62.94
- William J. Link, PhD · June 15, 2026 · Sale10.6K @ $61.97
- Katherine Goodrich · June 12, 2026 · Option Exercise3.0K
- Andrew D. Goldberg · June 12, 2026 · Option Exercise3.0K
- Scott W. Morrison · June 12, 2026 · Option Exercise3.0K
- Bhaskar Chaudhuri · June 12, 2026 · Option Exercise3.0K
- William J. Link, PhD · June 12, 2026 · Option Exercise3.0K
- Wendy L. Yarno · June 12, 2026 · Option Exercise3.0K
- David E. I. Pyott · April 24, 2026 · Option Exercise1.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 44.90M
- Total value held
- $3.06B
- Institutional holders
- 246
- Unknown3.60M
- Unknown3.55M
- Unknown3.35M
- Unknown2.56M
- Unknown2.24M
- Unknown1.94M
- Unknown1.76M
- Unknown1.71M
- Unknown1.28M
- Unknown1.19M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.